Galderma to Acquire ZO Skin Health for USD 1.5 Billion to Strengthen Dermatological Skincare Portfolio

The global skincare industry is witnessing increasing demand for science-backed products that combine dermatological expertise with daily skincare routines.

As consumers seek personalized solutions for skin health, established healthcare companies are expanding their portfolios through strategic acquisitions and investment in clinically supported skincare brands. Physician-dispensed products are also gaining attention for their connection with dermatologists, plastic surgeons, and other skincare professionals.

On October 14, 2026, Galderma announced that it had signed an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion. The transaction will bring together two companies with complementary capabilities in dermatological skincare, strengthening Galderma’s position in the physician-dispensed skincare segment.

The acquisition will expand Galderma’s existing portfolio, which includes Cetaphil and Alastin, while providing ZO Skin Health with access to Galderma’s global presence, research and development capabilities, and commercial network. The all-cash transaction remains subject to regulatory approvals and customary closing conditions. Completion is expected in the fourth quarter of 2026 or early 2027

Strengthening the Dermatological Skincare Portfolio

The primary objective of the acquisition is to expand Galderma’s presence in professional skincare by combining established brands with different product approaches. Galderma operates across injectable aesthetics, dermatological skincare, and therapeutic dermatology, giving it a broad position within the dermatology industry.

ZO Skin Health was founded by dermatologist Dr. Zein Obagi and is headquartered in Irvine, California. The company develops skincare products based on clinical science and structures daily care regimens. Its portfolio includes more than 40 products designed to support different skincare needs through professional guidance and daily use.

The acquisition will complement Galderma’s existing brands, particularly Alastin, which focuses on peptide-based regenerative skincare and pre- and post-procedure support. ZO Skin Health offers daily skincare regimens centered on retinol-and acid-based protocols.

Combining these portfolios could help Galderma provide healthcare professionals and patients with a broader selection of skincare solutions. The strategy also supports the company’s efforts to strengthen its relationship with dermatologists, plastic surgeons, and aesthetic professionals.

Acquisition Value and Transaction Structure

Galderma will acquire 100% of ZO Skin Health for an enterprise value of $1.5 billion through an all-cash transaction, subject to customary adjustments. The company plans to fund the acquisition through a combination of existing cash reserves and bank financing.

According to the announcement, ZO Skin Health recorded approximately $330 million in net sales during the 12 months ending June 2026. This provides Galderma with an established business, an existing customer base, and a portfolio of products already distributed across multiple international markets.

The acquisition is expected to be neutral to Galderma’s core earnings per share in the first full year following completion. The company also expects the transaction to cause slight dilution to its core EBITDA margin in 2027, with margins becoming broadly comparable to the group average from 2028 onward.

Galderma has indicated that it plans to increase commercial investment during the first year of ownership. The objective is to strengthen the business and support renewed growth beginning in the second year following closing.

Expanding Global Commercial Reach

A significant feature of the acquisition is the opportunity to combine ZO Skin Health’s established distribution network with Galderma’s international commercial capabilities.

ZO Skin Health sells its products through more than 16,500 physician, medical spa, and online accounts across over 40 countries. Its operations are supported by a dedicated salesforce and skincare education team, while its products are manufactured in the United States.

Galderma operates in approximately 90 countries and has experience supporting dermatology brands through research, education, product development, and commercial expansion. These capabilities could help ZO Skin Health strengthen its market presence and reach additional healthcare professionals and consumers.

Galderma’s integrated dermatology strategy may also create opportunities to improve professional education, increase brand visibility, and support product innovation. However, the extent of these benefits will depend on how effectively the company integrates the acquired business and executes its growth plans.

Growth Opportunities in Physician-Dispensed Skincare

The acquisition reflects the growing strategic importance of medical-grade skincare within the broader dermatology industry. Consumers are increasingly interested in products supported by dermatological expertise, while healthcare professionals are looking for solutions that complement clinical treatments and ongoing skincare routines.

Physician-dispensed skincare provides an opportunity for companies to connect professional recommendations with daily skin maintenance. Brands operating in this segment can benefit from relationships with dermatologists, product education, and structured skincare programs tailored to different needs.

For Galderma, the addition of ZO Skin Health could strengthen its ability to serve this demand through a wider range of products and professional channels. Its existing expertise in dermatological skincare and aesthetic treatments may also support opportunities to develop more integrated offerings for healthcare professionals and their patients.

Nevertheless, growth will depend on consumer demand, product differentiation, pricing, distribution effectiveness, and continued investment in innovation. Companies must also ensure that product claims remain consistent with available scientific evidence and applicable regulatory requirements.

Strategic Importance for Galderma

The agreement represents a significant step in Galderma’s strategy to build a broader dermatology portfolio. Rather than relying exclusively on internal product development, the company is using an acquisition to add an established brand with existing revenue, distribution relationships, and professional recognition.

For ZO Skin Health, joining Galderma could provide additional resources to support commercial expansion and product innovation. The acquisition may also help the brand benefit from a larger international organization with established capabilities across several areas of dermatology.

However, successful integration will require careful management of brand positioning, distribution channels, professional relationships, and product development priorities. Galderma will need to preserve ZO Skin Health’s distinctive identity while identifying opportunities to improve its long-term performance.

The transaction’s financial impact will also require monitoring as integration costs and planned commercial investments affect profitability during the initial ownership period.

Conclusion

Galderma’s agreement to acquire ZO Skin Health for $1.5 billion marks an important development in the dermatological skincare industry. The transaction will expand its portfolio alongside Cetaphil and Alastin, strengthening its presence in the physician-dispensed skincare segment.

With ZO Skin Health’s established international distribution network and Galderma’s global commercial capabilities, the acquisition offers opportunities to expand professional skincare offerings and support future growth. The company expects to complete the transaction in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions.

The long-term success of the acquisition will depend on effective integration, continued product innovation, commercial execution, and the ability to deliver value to healthcare professionals and consumers.

As the demand for science-backed skincare continues to evolve, strategic acquisitions may become an increasingly important route for dermatology companies seeking to expand their portfolios and strengthen their competitive positions.